Healthcare use from 2002 to 2011
| 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | ||||||||||
| Any DMARDs (%) | 86.3 | 84.9 | 87.3 | 87.1 | 80.8 | 84.5 | 84.4 | 85.5 | 86.0 | 85.8 |
| Synthetic DMARDs (%) | 84.0 | 81.1 | 82.4 | 79.7 | 72.6 | 77.8 | 77.0 | 76.5 | 77.9 | 76.9 |
| Biologics (%) | 4.4 | 8.2 | 9.6 | 14.0 | 16.8 | 16.2 | 19.4 | 23.4 | 23.9 | 25.2 |
| Other antirheumatic drugs (%) | 86.3 | 87.1 | 85.2 | 96.7 | 96.7 | 95.4 | 96.4 | 95.1 | 91.2 | 84.1 |
| Hospitalisation (%) | 19.6 | 17.2 | 17.6 | 16.9 | 16.2 | 16.8 | 18.2 | 16.7 | 16.9 | 16.3 |
| Duration in days (mean±SD) | 20.8±17.7 | 21.1±15.4 | 20.5±20.7 | 18.1±22.8 | 15.3±15.5 | 16.2±14.0 | 16.1±15.0 | 14.3±8.4 | 14.7±9.9 | 13.5±8.0 |
| Rehabilitation (%) | 12.9 | 10.8 | 9.7 | 10.4 | 9.5 | 12.4 | 12.1 | 11.9 | 24.5 | 11.3 |
| Duration in weeks (mean±SD*) | 3.6±1.2 | 3.8±3.1 | 3.6±1.8 | 3.5±0.2 | 3.6±0.2 | 3.5±0.2 | 3.5±0.2 | 3.5±1.8 | 3.8±2.5 | 3.3±1.7 |
| Physiotherapy (%) | 51.2 | 49.5 | 48.4 | 45.9 | 45.9 | 30.6 | 22.0 | 33.4 | 42.6 | 46.2 |
| Joint replacement surgery (%) | 2.3 | 2.2 | 2.1 | 3.5 | 3.5 | 2.5 | 1.9 | 3.5 | 3.2 | 3.5 |
| Imaging (%) | 85.1 | 82.7 | 82.5 | 83.0 | 69.9 | 75.8 | 67.3 | 71.3 | 72.4 | 72.5 |
| Age 18–64 years | ||||||||||
| Any DMARDs (%) | 89.0 | 86.3 | 88.5 | 88.3 | 81.8 | 85.7 | 84.3 | 87.3 | 88.0 | 86.9 |
| Synthetic DMARDs (%) | 86.5 | 81.7 | 82.7 | 78.6 | 71.6 | 77.4 | 75.5 | 77.5 | 78.8 | 76.6 |
| Biologics (%) | 5.6 | 10.0 | 11.8 | 18.1 | 21.3 | 20.9 | 24.2 | 29.4 | 31.6 | 31.2 |
| Other antirheumatic drugs (%) | 85.4 | 85.1 | 83.0 | 95.8 | 95.8 | 93.8 | 95.2 | 93.1 | 88.9 | 79.7 |
| Hospitalisation (%) | 21.6 | 18.4 | 19.4 | 17.0 | 16.1 | 16.1 | 18.7 | 18.0 | 17.0 | 16.9 |
| Duration in days (mean±SD) | 18.9±15.0 | 19.2±13.6 | 19.4±21.1 | 15.5±13.2 | 14.4±11.2 | 16.2±17.0 | 16.4±18.2 | 12.9±7.7 | 14.1±9.1 | 13.7±9.2 |
| Mean duration of hospitalisation in days in the general population aged 45–64 years | 9.2 | 8.8 | 8.6 | 8.6 | 8.5 | 8.3 | 8.1 | 8.0 | 7.9 | 7.7 |
| Rehabilitation (%) | 14.4 | 11.1 | 10.7 | 11.4 | 10.0 | 12.6 | 12.3 | 11.7 | 23.5 | 12.3 |
| Duration in weeks (mean± SD*) | 3.5±1.1 | 4.1±4.0 | 3.7±2.0 | 3.5±0.2 | 3.6±0.2 | 3.5±0.2 | 3.5±0.2 | 3.7±1.8 | 3.8±2.3 | 3.4±1.6 |
| Physiotherapy (%) | 51.2 | 50.1 | 48.2 | 42.0 | 41.9 | 31.5 | 22.5 | 32.0 | 44.2 | 46.2 |
| Joint replacement surgery (%) | 2.2 | 1.9 | 1.8 | 2.5 | 2.8 | 1.9 | 0.9 | 1.9 | 2.0 | 2.2 |
| Imaging (%) | 84.5 | 83.5 | 83.2 | 85.0 | 69.1 | 75.0 | 65.5 | 69.7 | 72.4 | 72.8 |
| Age ≥65 years | ||||||||||
| Any DMARDs (%) | 82.5 | 83.1 | 85.9 | 85.7 | 79.6 | 83.3 | 84.6 | 83.8 | 84.3 | 84.8 |
| Synthetic DMARDs (%) | 80.6 | 80.3 | 82.1 | 81.1 | 73.7 | 78.2 | 78.5 | 75.7 | 77.2 | 77.1 |
| Biologics (%) | 2.8 | 6.0 | 7.0 | 9.0 | 11.7 | 11.7 | 14.7 | 18.0 | 17.5 | 19.2 |
| Other antirheumatic drugs (%) | 87.5 | 89.6 | 87.9 | 97.4 | 97.4 | 96.9 | 97.4 | 96.8 | 93.2 | 88.5 |
| Hospitalisation (%) | 16.8 | 15.5 | 15.4 | 16.7 | 16.3 | 17.6 | 17.6 | 15.4 | 16.8 | 15.7 |
| duration in days (mean±SD) | 24.6±21.9 | 24.1±17.6 | 22.1±20.2 | 21.9±31.3 | 16.3±19.3 | 16.1±9.9 | 15.8±9.9 | 15.9±8.9 | 15.2±10.6 | 13.2±6.2 |
| Mean duration of hospitalisation in days in the general population aged ≥65 years | 11.4 | 10.8 | 10.4 | 10.3 | 10.0 | 9.9 | 9.6 | 9.4 | 9.2 | 9.0 |
| Rehabilitation (%) | 10.6 | 10.3 | 8.4 | 9.3 | 8.8 | 12.2 | 11.8 | 12.1 | 25.4 | 10.1 |
| Duration in weeks (mean±SD*) | 3.7±1.4 | 3.3±0.9 | 3.4±1.3 | 3.5±0.2 | 3.6±0.2 | 3.6±0.3 | 3.5±0.2 | 3.3±1.8 | 3.8±2.8 | 3.2±1.9 |
| Physiotherapy (%) | 49.0 | 48.9 | 46.6 | 50.7 | 50.3 | 29.7 | 21.5 | 34.8 | 41.3 | 46.3 |
| Joint replacement surgery (%) | 2.4 | 2.6 | 2.5 | 4.4 | 4.2 | 2.9 | 2.9 | 4.9 | 4.2 | 4.7 |
| Imaging (%) | 85.9 | 81.8 | 81.8 | 80.8 | 70.7 | 76.5 | 68.9 | 72.7 | 72.4 | 72.2 |
*The duration of inpatient rehabilitation was not collected from 2005–2008; this duration was imputed by the mean duration from 2000 to 2004, stratified for function (FFbH). Consequently, we observed low SDs.
DMARD, disease modifying antirheumatic drugs. Italic font indicates data that are not from our data source but from other sources for comparison.